Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers

Epigenetics

Volumn 8, Issue 6, 2013, Pages 624-634

  Huang, Rui Lan ^a   Gu, Fei ^a   Kirma, Nameer B ^a   Ruan, Jianhua ^a   Chen, Chun Liang ^a   Wang, Hui Chen ^a   Liao, Yu Ping ^a   Chang, Cheng Chang ^a   Yu, Mu Hsien ^a   Pilrose, Jay M ^a   Thompson, Ian M ^a   Huang, Hsuan Cheng ^a   Huang, Tim Hui Ming ^a   Lai, Hung Cheng ^a   Nephew, Kenneth P ^a  

^a NONE

Author keywords

DNA methylation; Hedgehog pathway; Ovarian cancer; ZIC1; ZIC4

Indexed keywords

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL VIABILITY; DISEASE COURSE; DNA METHYLATION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY TUMOR; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

ERINACEIDAE;

EID: 84891959461     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.24816     Document Type: Article

References (52)

1. Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Semin Oncol 2007; 34:S1-15; PMID: 17512352; DOI: 10.1053/j.seminoncol.2007.03.012.
2. Liu CM. Cancer of the ovary. N Engl J Med 2005; 352:1268-9, author reply 1268-9; PMID: 15791705; DOI: 10.1056/NEJM200503243521222.
3. Sandercock J, Parmar MK, Torri V, Qian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 2002; 87:815-24; PMID: 12373593; DOI: 10.1038/sj.bjc.6600567.
4. Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, Rose SL. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics 2008; 1:47; PMID: 18826610; DOI: 10.1186/1755-8794-1-47.
5. Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002; 8:2246-52; PMID: 12114427.
6. Barton CA, Hacker NF, Clark SJ, O'Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008; 109:129-39; PMID: 18234305; DOI: 10.1016/j.ygyno.2007.12.017.
7. Balch C, Fang F, Matei DE, Huang TH, Nephew KP. Minireview: epigenetic changes in ovarian cancer. Endocrinology 2009; 150:4003-11; PMID: 19574400; DOI: 10.1210/en.2009-0404.
8. Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004; 64:6476-81; PMID: 15374957; DOI: 10.1158/0008-5472.CAN-04-1529.
9. Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ, et al. HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer. Int J Cancer 2008; 123:725-9; PMID: 18478570; DOI: 10.1002/ijc.23563.
10. Shridhar V, Bible KC, Staub J, Avula R, Lee YK, Kalli K, et al. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res 2001; 61:4258-65; PMID: 11358853.
11. Akahira J, Sugihashi Y, Suzuki T, Ito K, Niikura H, Moriya T, et al. Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res 2004; 10:2687-93; PMID: 15102672; DOI: 10.1158/1078-0432.CCR-03-0510.
12. Wei SH, Balch C, Paik HH, Kim YS, Baldwin RL, Liyanarachchi S, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 2006; 12:2788-94; PMID: 16675572; DOI: 10.1158/1078-0432.CCR-05-1551.
13. Chan MW, Wei SH, Wen P, Wang Z, Matei DE, Liu JC, et al. Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res 2005; 11:7376-83; PMID: 16243810; DOI: 10.1158/1078-0432.CCR-05-1100.
14. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005; 65:8961-7; PMID: 16204069; DOI: 10.1158/0008-5472.CAN-05-1187.
15. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 2005; 11:5365-9; PMID: 16061849; DOI: 10.1158/1078-0432.CCR-04-2455.
16. Gloss BS, Patterson KI, Barton CA, Gonzalez M, Scurry JP, Hacker NF, et al. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers. Cancer Lett 2012; 318:76-85; PMID: 22155104; DOI: 10.1016/j.canlet.2011.12.003.
17. Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM, et al. Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther 2012; 11:1587-97; PMID: 22553355; DOI: 10.1158/1535-7163.MCT-11-1058.
18. Bhattacharya R, Kwon J, Ali B, Wang E, Patra S, Shridhar V, et al. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res 2008; 14:7659-66; PMID: 19047091; DOI: 10.1158/1078-0432.CCR-08-1414.
19. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309:883-7; PMID: 6310399; DOI: 10.1056/NEJM198310133091503.
20. Liao X, Siu MK, Au CW, Wong ES, Chan HY, Ip PP, et al. Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis 2009; 30:131-40; PMID: 19028702; DOI: 10.1093/carcin/bgn230.
21. Gan L, Chen S, Zhong J, Wang X, Lam EK, Liu X, et al. ZIC1 is downregulated through promoter hypermethylation, and functions as a tumor suppressor gene in colorectal cancer. PLoS One 2011; 6:e16916; PMID: 21347233; DOI: 10.1371/journal.pone.0016916.
22. Wang LJ, Jin HC, Wang X, Lam EK, Zhang JB, Liu X, et al. ZIC1 is downregulated through promoter hypermethylation in gastric cancer. Biochem Biophys Res Commun 2009; 379:959-63; PMID: 19135984; DOI: 10.1016/j.bbrc.2008.12.180.
23. Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-15; PMID: 21720365; DOI: 10.1038/nature10166.
24. Mizugishi K, Aruga J, Nakata K, Mikoshiba K. Molecular properties of Zic proteins as transcriptional regulators and their relationship to GLI proteins. J Biol Chem 2001; 276:2180-8; PMID: 11053430; DOI: 10.1074/jbc.M004430200.
25. Bauerschlag DO, Ammerpohl O, Bräutigam K, Schem C, Lin Q, Weigel MT, et al. Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. Oncology 2011; 80:12-20; PMID: 21577013; DOI: 10.1159/000327746.
26. Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, Flanagan JM, et al. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 2011; 17:4052-62; PMID: 21459799; DOI: 10.1158/1078-0432.CCR-10-3021.
27. Jones A, Lechner M, Fourkala EO, Kristeleit R, Widschwendter M. Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers. Epigenomics 2010; 2:9-38; PMID: 22122746; DOI: 10.2217/epi.09.47.
28. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999; 96:8681-6; PMID: 10411935; DOI: 10.1073/pnas.96.15.8681.
29. Issa JP. Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. Clin Cancer Res 2003; 9:2879-81; PMID: 12912930.
30. Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J, et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001; 158:1121-7; PMID: 11238060; DOI: 10.1016/S0002-9440(10)64059-X.
31. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000; 60:1835-9; PMID: 10766168.
32. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59:5438-42; PMID: 10554013.
33. Zhang QY, Yi DQ, Zhou L, Zhang DH, Zhou TM. Status and significance of CpG island methylator phenotype in endometrial cancer. Gynecol Obstet Invest 2011; 72:183-91; PMID: 21968189; DOI: 10.1159/000324496.
34. Kolbe DL, DeLoia JA, Porter-Gill P, Strange M, Petrykowska HM, Guirguis A, et al. Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype. PLoS One 2012; 7:e32941; PMID: 22403726; DOI: 10.1371/journal.pone.0032941.
35. Ahluwalia A, Hurteau JA, Bigsby RM, Nephew KP. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol 2001; 82:299-304; PMID: 11531283; DOI: 10.1006/gyno.2001.6284.
36. Bai X, Song Z, Fu Y, Yu Z, Zhao L, Zhao H, et al. Clinicopathological significance and prognostic value of DNA methyltransferase 1, 3a, and 3b expressions in sporadic epithelial ovarian cancer. PLoS One 2012; 7:e40024; PMID: 22768205; DOI: 10.1371/journal.pone.0040024.
37. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21:5400-13; PMID: 12154403; DOI: 10.1038/sj.onc.1205651.
38. Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 2005; 65:828-34; PMID: 15705880.
39. Shen L, Catalano PJ, Benson AB, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007; 13:6093-8; PMID: 17947473; DOI: 10.1158/1078-0432.CCR-07-1011.
40. An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005; 11:656-63; PMID: 15701853.
41. Jo P, Jung K, Grade M, Conradi LC, Wolff HA, Kitz J, et al. CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. Surgery 2012; 151:564-70; PMID: 22001634; DOI: 10.1016/j.surg.2011.08.013.
42. Ling Y, Huang G, Fan L, Wei L, Zhu J, Liu Y, et al. CpG island methylator phenotype of cell-cycle regulators associated with TNM stage and poor prognosis in patients with oesophageal squamous cell carcinoma. J Clin Pathol 2011; 64:246-51; PMID: 21169275; DOI: 10.1136/jcp.2010.082875.
43. Koyabu Y, Nakata K, Mizugishi K, Aruga J, Mikoshiba K. Physical and functional interactions between Zic and Gli proteins. J Biol Chem 2001; 276:6889-92; PMID: 11238441; DOI: 10.1074/jbc.C000773200.
44. Grinberg I, Millen KJ. The ZIC gene family in development and disease. Clin Genet 2005; 67:290-6; PMID: 15733262; DOI: 10.1111/j.1399-0004.2005.00418.x.
45. Marchini S, Poynor E, Barakat RR, Clivio L, Cinquini M, Fruscio R, et al. The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer. Clin Cancer Res 2012; 18:4313-24; PMID: 22733541; DOI: 10.1158/1078-0432.CCR-12-0037.
46. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006; 5:1026-33; PMID: 17139287; DOI: 10.1038/nrd2086.
47. Ruiz i Altaba A, Mas C, Stecca B. The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol 2007; 17:438-47; PMID: 17845852; DOI: 10.1016/j.tcb.2007.06.007.
48. Kudo K, Gavin E, Das S, Amable L, Shevde LA, Reed E. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene 2012; 31:4718-24; PMID: 22266871; DOI: 10.1038/onc.2011.610.
49. Su HY, Lai HC, Lin YW, Liu CY, Chen CK, Chou YC, et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 2010; 127:555-67; PMID: 19957335; DOI: 10.1002/ijc.25083.
50. Huang TT, Gonzales CB, Gu F, Hsu YT, Jadhav RR, Wang CM, et al. Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas. Carcinogenesis 2013; PMID: 23568951; DOI: 10.1093/carcin/bgt112.
51. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009; 2:34; PMID: 19505326; DOI: 10.1186/1755-8794-2-34.
52. Balch C, Yan P, Craft T, Young S, Skalnik DG, Huang TH, et al. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 2005; 4:1505-14; PMID: 16227399; DOI: 10.1158/1535-7163.MCT-05-0216.